Supernus Pharmaceuticals
In Howard Marks's portfolio · Oaktree Capital Management
Ticker SUPN.CV
Not in the portfolio as of Q2 2026. Every quarter it shows up in a Oaktree Capital Management 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q3 2022 | Add 3% | 25,143,000 | 0.3% |
| Q2 2022 | Add 23% | 24,447,000 | 0.3% |
| Q2 2021 | Reduce 1% | 22,488,000 | 0.3% |
| Q1 2021 | Add 36% | 22,802,000 | 0.3% |
| Q4 2020 | Add 101% | 16,738,000 | 0.3% |
| Q2 2020 | Buy | 16,511,000 | 0.3% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.